ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
National and Kapodistrian University of Athens
Atenas, GreciaPublicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (16)
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Melflufen for the treatment of multiple myeloma
Expert Review of Clinical Pharmacology
2021
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2019
-
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
Leukemia and Lymphoma, Vol. 60, Núm. 2, pp. 462-470
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107
2018
-
Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel
Journal of Hematology and Oncology, Vol. 11, Núm. 1
2017
-
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
Leukemia, Vol. 31, Núm. 11, pp. 2443-2448
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma
Blood, Vol. 128, Núm. 4, pp. 497-503
2014
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
Leukemia, Vol. 28, Núm. 3, pp. 525-542
-
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial
The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206
2013
-
Response assessment in Waldenström macroglobulinaemia: Update from the VIth International Workshop
British Journal of Haematology, Vol. 160, Núm. 2, pp. 171-176
2009
-
International prognostic scoring system for Waldenström macroglobulinemia
Blood, Vol. 113, Núm. 18, pp. 4163-4170
-
Update on treatment recommendations from the fourth international workshop on Waldenström's macroglobulinemia
Journal of Clinical Oncology, Vol. 27, Núm. 1, pp. 120-126
2006
-
Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia
Clinical Lymphoma and Myeloma, Vol. 6, Núm. 5, pp. 380-383